activity
serum
alpha
amylase
cystic
fibrosis
new
method
us
differential
inhibitor
measure
pancreatic
salivary
type
alpha
amylase
ec
applied
serum
sample
cystic
fibrosis
cf
patient
age
range
year
control
age
group
level
pancreatic
type
amylase
lower
cf
patient
median
u
control
median
p
le
result
salivary
type
enzyme
however
support
previously
reported
finding
higher
usual
level
cf
patient
discrepancy
probably
due
difference
analytical
method
felt
procedure
value
investigation
patient
cystic
fibrosis
pancreatic
disorder
